PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsRifapentine
Rifapentine
Priftin (rifapentine) is a small molecule pharmaceutical. Rifapentine was first approved as Priftin on 1998-06-22. It is used to treat latent tuberculosis, mycobacterium infections, and pulmonary tuberculosis in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
Trade Name
FDA
EMA
Priftin
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rifapentine
Tradename
Company
Number
Date
Products
PRIFTINSanofiN-021024 RX1998-06-22
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
priftinNew Drug Application2024-07-12
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
J04: Antimycobacterials
J04A: Drugs for treatment of tuberculosis
J04AB: Antibiotics, antitubercular
J04AB05: Rifapentine
HCPCS
No data
Clinical
No data
Drug
General
Drug common nameRifapentine
INNrifapentine
Description
Rifapentine, sold under the brand name Priftin, is an antibiotic used in the treatment of tuberculosis. In active tuberculosis it is used together with other antituberculosis medications. In latent tuberculosis it is typically used with isoniazid. It is taken by mouth.
Classification
Small molecule
Drug classantibiotics (rifamycin derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C6CCCC6)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
Identifiers
PDB
CAS-ID61379-65-5
RxCUI
ChEMBL IDCHEMBL1660
ChEBI ID45304
PubChem CID6323497
DrugBankDB01201
UNII IDXJM390A33U (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use